Tobira Therapeutics Inc (TBRA) was Downgraded by Cantor Fitzgerald to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Cantor Fitzgerald advised their investors in a research report released on Sep 21, 2016.
Many Wall Street Analysts have commented on Tobira Therapeutics Inc. Cantor Fitzgerald Initiated Tobira Therapeutics Inc on Jul 6, 2016 to “Buy”, Price Target of the shares are set at $27.
Tobira Therapeutics Inc opened for trading at $33 and hit $41.39 on the upside on Tuesday, eventually ending the session at $38.91, with a gain of 720.89% or 34.17 points. The heightened volatility saw the trading volume jump to 1,27,64,728 shares. Company has a market cap of $732 M.
Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Companys lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.